Gilead Sciences Aktie News

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit above Wall Street estimates.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. “We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and positive data for Trodelvy in 1L metastatic triple negative breast cancer,” said Daniel O'Day, Gilea...

WASHINGTON--(BUSINESS WIRE)--Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes.

Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.

Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On October 23, Gilead announced that it will announce data on the switching of people with PBC from obeticholic acid to its 'rising star' Livdelzi at The Liver Meeting 2025.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), November 7-11 in Washington, D.C. Key findings from more than 35 accepted abstracts across PBC and v...

WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead's leadership in advancing a...